Project R-1916

SialoTarg: Advanced vaccines and pharmaceuticals targeted to macrophages via sialoadhesin (Research)

Technology development for targeting to specific immune cells. Recently, a new receptor was identified as a protein exclusively expressed on specific immune cells. Because of the important role of these immune cells in the immune system, targeted manipulation of these cells via this receptor might be promising in steering immunity. Therefore, we are developing a technology that can either provoke, subtly modify or completely eradicate an immune response. To evaluate if the technology can be used for treatment of multiple sclerosis (MS), we aim to study expression levels of this receptor on immune cells in clinical samples of MS patients and healthy controls. In addition, preclinical targeting of the receptor will be performed in an animal model of MS. This project will elucidate whether this technology can result in a better and safer treatment of MS.

01 March 2009 - 28 February 2013